Clinical Trial Update: EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 pilot trial evaluating Tumor Treating Fields (TTFields) in combination with pembrolizumab as first-line therapy for advanced or metastatic non-small c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Tumor Treating Fields (tumor treating fields)

Snippet

Sponsor: NovoCure GmbH | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: TERMINATED